Logged in as: Guest
WCN'24 Home
View detailed Congress Program
View Program at a glance
LOGIN
Efficacy and safety of zibotentan in combination with dapagliflozin in patients with CKD according to baseline diabetes status and kidney function
Back
E-Poster
https://storage.unitedwebnetwork.com/files/1099/abfa1b2071a18f166b1f7febfa562701.pdf
Abstract Title
Efficacy and safety of zibotentan in combination with dapagliflozin in patients with CKD according to baseline diabetes status and kidney function
First Name *
Hiddo
Last Name *
Lambers Heerspink
Co-author 1
Arihiro Kiyosue kiyosue-tky@umin.ac.jp University of Tokyo Medicine Tokyo
Co-author 2
David Wheeler d.wheeler@ucl.ac.uk University College London Nephrology London
Co-author 3
Min Lin annie.lin1@astrazeneca.com AstraZeneca Biometrics Late Development, Cardiovascular, Renal and Metabolism Gaithersburg
Co-author 4
Emma Wijkmark emma.wikmark@astrazeneca.com AstraZeneca Biometrics Late Development, Cardiovascular, Renal and Metabolism Gothenburg
Co-author 5
Glenn Carlson glenn.carlson@astrazeneca.com AstraZeneca Clinical Late Development CVRM Gaithersburg
Co-author 6
Anne-Kristina Mercier tina.mercier@astrazeneca.com AstraZeneca Clinical Pharmacology and Quantitative Pharmacology Gothenburg
Co-author 7
Magnus Astrand magnus.astrand@astrazeneca.com AstraZeneca Clinical Pharmacology and Quantitative Pharmacology Gothenburg
Co-author 8
Sebastian Ueckert sebastian.ueckert@astrazeneca.com AstraZeneca Clinical Pharmacology and Quantitative Pharmacology Gothenburg
Co-author 9
Peter J Greasley peter.greasley@astrazeneca.com AstraZeneca Research and Early Development CVRM Gothenburg
Co-author 10
Phil Ambery phil.ambery@astrazeneca.com AstraZeneca Clinical Late Development CVRM Gothenburg
Co-author 11
Co-author 12
Co-author 13
Co-author 14
Co-author 15
